In the case of low viral circulation, the benefit of receiving Anglo-Swedish serum decreases with age: according to EMA data, in the 20-29 age group, the chance of thrombosis after every 100,000 vaccination is 1.9, And 4 out of 100,000 opportunities to avoid hospitalization. According to data from the University of Cambridge, this gap is even smaller. It is estimated that the probability of avoiding hospitalization in intensive care is 0.8 out of every 100,000 doses, while the probability of thrombosis is 1.1.
AstraZeneca’s anti-coronavirus vaccine re-split experts after the following conditions occurred An 18 year old girl After receiving viral vector serum, he was hospitalized with cavernous sinus thrombosis. On the one hand, it is the opportunity represented by the youngest open day. On the other hand, it is the doubt about the adequacy of drugs for people under 60, especially women.In Italy, the indications recommended by the Aifa Drug Agency Priority use over 60 years old, And the European EMA agency has not yet set any restrictions. However, at present, after the appeal of the Luca Coscioni Association, AstraZeneca vaccines and Johnson & Johnson’s vaccines are always based on the assumption that adenovirus vectors are no longer suitable for young people. Suspend the use of these two preparations for vaccination under the age of 30, and also take into account the available doses of Pfizer-BioNTech and Moderna, which are produced using messenger RNA technology.
The benefit/risk balance of AstraZeneca vaccine
But what does the data show?Why, as pointed out By several experts, Should we choose a safer vaccine based on age? “Due to the low transmission rate of the virus, AstraZeneca’s risks may outweigh the benefits for people under 30“He is in a tweet, Occupy one EMA file Nino Cartabellotta, Chairman of the Kimbe Foundation, published on April 23.
The graph shows that the risk-benefit ratio based on age in the case of low virus transmission is comparable to the current situation in Italy.Clearly indicate in the different columns how 20-29 years old age group There is a 4 in 100,000 chance of avoiding hospitalization due to Covid-19, and the chance of thrombosis after the AstraZeneca vaccine is 1 in 100,000. In contrast, in the 60-69 age group, only 1 out of 19 avoided hospitalizations had thrombosis. More obvious is the data related to the risk of intensive care hospitalization. Among 100,000 children between the ages of 20 and 29, the risk is zero, while AstraZeneca has a thrombosis probability of 1.9. Compared with the risk of thromboembolism, so is the risk of death.
as well UN report The University of Cambridge published in the United Kingdom under the condition of low virus transmission, it emphasized that the relationship between the benefits and risks of AstraZeneca vaccination gradually decreases with age, indicating that it is in the range of 20-29 years old 0.8 odds per 100,000 people Compared with 1.1 the possibility of thrombosis after vaccination, avoid admission to the ICU. On the other hand, in the 60-69 age group, this ratio is clearly conducive to the benefits of vaccination. Compared with 0.2 cases of thromboembolism, the probability of avoiding hospitalization in intensive care is 14.1.